Clinically superior scalp cooling

Hair loss is no longer inevitable

FDA cleared for men and women with solid tumor cancers

1 2 3

Clinically superior scalp cooling

Hair loss is no longer inevitable

FDA cleared for men and women with solid tumor cancers

1 2 3

Dignitana AB produces
The DigniCap Scalp Cooling System to minimize hair loss from chemotherapy.

Click HERE to learn more about DigniCap Delta.

The patented DigniCap system has shown excellent scientific results in clinical studies– 67% of patients had a successful outcome and retained their hair in the pivotal trial which led to FDA clearance in 2015.

For product information, visit dignicap.com

ABOUT DIGNITANA READ MORE

Company Profile

Dignitana is a Swedish medical technology company publicly traded on Nasdaq First North Growth Market. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy.

The company develops, produces and markets The DigniCap® Scalp Cooling System. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. In 2017, Dignitana received an expanded clearance from the FDA, allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lungs and other tissues.

ANNOUNCEMENTS

Dignitana appoints Nomination Committee for Annual General Meeting which will be held on 22 May 2025.

Read more here
Shareholders wishing to make suggestions to the Nomination Committee may write to investorrelations@dignitana.com by 1 April 2025 at the latest.

LATEST PRESS RELEASES

Dignitana AB Publishes Q4 2024 Interim Report

2025-02-20

Strong finish to 2024 – record high sales in Q4 Financial highlights Q4 2024 · Net Sales amounted to 24.0 MSEK (21.3), an increase of 13 percent over the same quarter in 2023. · Operating Result amounted to -1.6 MSEK (-3.7). · Net Result after financial items amounted to -1.1 MSEK (-4.9). · EBITDA for…

ANALYSIS

Dignitana: interview with CEO Fredrik Jonsson

22 August 2024

Redeye har intervjuat Fredrik Jonsson, VD för Dignitana. Vi diskuterade Fredriks inträde som ny VD och visionerna för bolaget framöver.

Watch the video interview in Swedish here

Dignitana: Intervju med vd Fredrik Jonsson

VIDEOS

Saving Identity

1 September 2019

In the film “Saving Identity” Dr. Hope Rugo of UCSF explains how scalp cooling reduces hair loss from chemo and the process from gaining approval for the first FDA cleared scalp cooling system in the US in 2015 to the launch of the new DigniCap Delta device in 2019.

Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.

HEADQUARTERS
Dignitana AB
Traktorgränden 3
226 60 Lund, Sweden
+46 46 16 30 90

UNITED STATES
Dignitana
10925 Estate Lane, Suite 185
Dallas, TX 75238
+1 469-917-5555

HEADQUARTERS
Dignitana S.r.l.
Corso di Porta Nuova, 46
20121 Milan, Italy

Dignitana AB producesThe DigniCap Scalp Cooling System to minimize hair loss from chemotherapy.

Company Profile

Dignitana AB Publishes Q4 2024 Interim Report

Dignitana AB produces
The DigniCap Scalp Cooling System to minimize hair loss from chemotherapy.